Dr Reddy’s focuses on differentiated portfolio in key therapy areas for growth in India: GlobalData
DRL has earlier this month divested nine dermatology brands to Eris Lifesciences for Rs 2750 million ($33.3 million*). Within a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
growth strategy
Jubilant Life Sciences to focus on operational, financial performance in near-term
To tide over the COVID-19 pandemic led crisis, the company in the near-term is deferring its major CAPEX plans, informs annual…
The new norm will be supply chain stress tests to build resilience
The COVID-19 crisis has thrown up unprecedented challenges and opportunities for the Indian pharma sector. Dr Arun Singh, Chief…